EA200301159A1 - Цитотоксические иммуноконъюгаты антитела к cd44 - Google Patents
Цитотоксические иммуноконъюгаты антитела к cd44Info
- Publication number
- EA200301159A1 EA200301159A1 EA200301159A EA200301159A EA200301159A1 EA 200301159 A1 EA200301159 A1 EA 200301159A1 EA 200301159 A EA200301159 A EA 200301159A EA 200301159 A EA200301159 A EA 200301159A EA 200301159 A1 EA200301159 A1 EA 200301159A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- conjugates
- application describes
- antibodies
- cytotoxic immunoconjugates
- cytotoxic
- Prior art date
Links
- 102100032912 CD44 antigen Human genes 0.000 title abstract 2
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 title abstract 2
- 231100000433 cytotoxic Toxicity 0.000 title abstract 2
- 230000001472 cytotoxic effect Effects 0.000 title abstract 2
- 229940127121 immunoconjugate Drugs 0.000 title abstract 2
- -1 3-mercapto-1-oxopropyl Chemical group 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01112227A EP1258255A1 (en) | 2001-05-18 | 2001-05-18 | Conjugates of an antibody to CD44 and a maytansinoid |
| PCT/EP2002/005413 WO2002094325A2 (en) | 2001-05-18 | 2002-05-16 | Cytotoxic cd44 antibody immunoconjugates |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA200301159A1 true EA200301159A1 (ru) | 2004-06-24 |
Family
ID=8177473
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA200301159A EA200301159A1 (ru) | 2001-05-18 | 2002-05-16 | Цитотоксические иммуноконъюгаты антитела к cd44 |
Country Status (24)
| Country | Link |
|---|---|
| EP (2) | EP1258255A1 (https=) |
| JP (1) | JP2004529963A (https=) |
| KR (1) | KR20030097883A (https=) |
| CN (1) | CN1509187A (https=) |
| AR (1) | AR035977A1 (https=) |
| BG (1) | BG108366A (https=) |
| BR (1) | BR0209862A (https=) |
| CA (1) | CA2443438A1 (https=) |
| CO (1) | CO5550468A2 (https=) |
| CZ (1) | CZ20033477A3 (https=) |
| EA (1) | EA200301159A1 (https=) |
| EE (1) | EE200300568A (https=) |
| HR (1) | HRP20030932A2 (https=) |
| HU (1) | HUP0400046A3 (https=) |
| IL (1) | IL157965A0 (https=) |
| MX (1) | MXPA03010432A (https=) |
| NO (1) | NO20035108L (https=) |
| NZ (1) | NZ530167A (https=) |
| PE (1) | PE20021097A1 (https=) |
| PL (1) | PL365480A1 (https=) |
| SK (1) | SK15582003A3 (https=) |
| WO (1) | WO2002094325A2 (https=) |
| YU (1) | YU91503A (https=) |
| ZA (1) | ZA200307364B (https=) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8071072B2 (en) * | 1999-10-08 | 2011-12-06 | Hoffmann-La Roche Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD44 |
| US6441163B1 (en) * | 2001-05-31 | 2002-08-27 | Immunogen, Inc. | Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents |
| US7084257B2 (en) | 2001-10-05 | 2006-08-01 | Amgen Inc. | Fully human antibody Fab fragments with human interferon-gamma neutralizing activity |
| EP1417974A1 (en) * | 2002-11-08 | 2004-05-12 | Boehringer Ingelheim International GmbH | Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and radiotherapy |
| US7384744B2 (en) | 2002-11-29 | 2008-06-10 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | Expression vector, methods for the production of heterologous gene products and for the selection of recombinant cells producing high levels of such products |
| DE10256083A1 (de) * | 2002-11-29 | 2004-08-12 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Expressionsvektor, Verfahren zur Herstellung von heterologen Genprodukten und Selektionsverfahren für hochproduzierende rekombinante Zellen |
| US7276497B2 (en) | 2003-05-20 | 2007-10-02 | Immunogen Inc. | Cytotoxic agents comprising new maytansinoids |
| PL3524611T3 (pl) * | 2003-05-20 | 2021-06-14 | Immunogen, Inc. | Udoskonalone czynniki cytotoksyczne zawierające nowe maitansynoidy |
| EA014640B1 (ru) * | 2003-07-21 | 2010-12-30 | Иммьюноджен, Инк. | Антитело или его эпитоп-связывающий фрагмент, которые связываются с гликотопом са6, и способы их применения |
| CA2556027C (en) | 2004-02-12 | 2015-11-24 | Morphotek, Inc. | Monoclonal antibodies that specifically block biological activity of a tumor antigen |
| PL1819359T3 (pl) * | 2004-12-09 | 2015-08-31 | Janssen Biotech Inc | Immunokoniugaty skierowane przeciw integrynie, metody ich wytwarzania oraz ich zastosowanie |
| CA2597407C (en) * | 2005-02-11 | 2013-09-10 | Immunogen, Inc. | Process for preparing stable drug conjugates |
| CA2600505C (en) | 2005-03-10 | 2016-05-03 | Morphotek, Inc. | Anti-mesothelin antibodies |
| ZA200708694B (en) * | 2005-04-15 | 2009-01-28 | Immunogen Inc | Elimination of heterogeneous or mixed cell population in tumors |
| EP2172487A1 (en) | 2005-04-22 | 2010-04-07 | Morphotek Inc. | Antibodies with Immune Effector Activity that Internalize in Folate Receptor Alpha-Positive Cells |
| EP3539572A1 (en) | 2005-08-24 | 2019-09-18 | ImmunoGen, Inc. | Process for preparing maytansinoid antibody conjugates |
| EP1806365A1 (en) | 2006-01-05 | 2007-07-11 | Boehringer Ingelheim International GmbH | Antibody molecules specific for fibroblast activation protein and immunoconjugates containing them |
| AR059900A1 (es) * | 2006-03-17 | 2008-05-07 | Genentech Inc | Anticuerpos anti-tat226 e inmunoconjugados |
| BRPI1010620B8 (pt) | 2009-06-03 | 2021-05-25 | Immunogen Inc | métodos de conjugação |
| AR078471A1 (es) * | 2009-10-02 | 2011-11-09 | Sanofi Aventis | COMPUESTOS MAITANSINOIDES Y EL USO DE ESTOS PARA PREPARAR CONJUGADOS CON UN ANTICUERPO LOS CUALES SE UTILIZAN COMO AGENTES ANTICANCERIGENOS Y EL PROCEDIMIENTO DE PREPARACIoN DE ESTOS CONJUGADOS |
| RS58367B1 (sr) | 2011-03-29 | 2019-03-29 | Immunogen Inc | Priprema konjugata antitela i majtanzinoida jednostepenim postupkom |
| CN102337298B (zh) * | 2011-08-19 | 2013-11-06 | 黄开红 | 一种输送siRNA的免疫纳米载体及其制备方法和应用 |
| WO2014055877A1 (en) | 2012-10-04 | 2014-04-10 | Immunogen, Inc. | Use of a pvdf membrane to purify cell-binding agent cytotoxic agent conjugates |
| GB201220899D0 (en) * | 2012-11-21 | 2013-01-02 | Kit Karlsrusher Inst Fuer Technologie Und Inst Fuer Toxikologie Und Genetik And Amcure Gmbh | CD44v6-derived pegylated peptides |
| GB201220889D0 (en) | 2012-11-21 | 2013-01-02 | Kit Karlsrusher Inst Fuer Technologie Und Inst Fuer Toxikologie Und Genetik And Amcure Gmbh | CD44v6-derived peptides for treating metastasizing cancers |
| GB201220891D0 (en) * | 2012-11-21 | 2013-01-02 | Kit Karlsrusher Inst Fuer Technologie Und Inst Fuer Toxikologie Und Genetik And Amcure Gmbh | CD44v6-derived peptides for treating breast cancers |
| GB201220901D0 (en) * | 2012-11-21 | 2013-01-02 | Kit Karlsrusher Inst Fuer Technologie Und Inst Fuer Toxikologie Und Genetik And Amcure Gmbh | CD44v6-derived peptides for treating pancreatic cancer |
| MX379256B (es) | 2013-03-15 | 2025-03-10 | Regeneron Pharma | Moleculas biologicamente activas, conjugados de las mismas, y usos terapeuticos. |
| KR102252925B1 (ko) | 2013-08-26 | 2021-05-18 | 리제너론 파마슈티칼스 인코포레이티드 | 마크롤라이드 디아스테레오머를 포함하는 약제학적 조성물, 이의 합성 방법 및 치료학적 용도 |
| GB201421647D0 (en) | 2014-12-05 | 2015-01-21 | Amcure Gmbh And Ruprecht-Karls-Universitat And Karlsruher Institut F�R Technologie | CD44v6-derived cyclic peptides for treating cancers and angiogenesis related diseases |
| WO2016150521A1 (en) * | 2015-03-26 | 2016-09-29 | Fundación Imdea Nanociencia | Functionalised magnetic nanoparticle |
| EA034950B1 (ru) | 2015-03-27 | 2020-04-09 | Регенерон Фармасьютикалз, Инк. | Производные майтанзиноида, их конъюгаты и способы использования |
| CN109661407A (zh) | 2016-06-06 | 2019-04-19 | 西北大学 | 融合蛋白构建体 |
| EP3755717A4 (en) * | 2018-02-22 | 2022-01-26 | Multitude Inc. | THERAPEUTIC ANTIBODY AND USES THEREOF |
| CN114057874B (zh) * | 2020-07-31 | 2023-05-05 | 北京市神经外科研究所 | 抗cd44的单链抗体及其在制备治疗肿瘤的药物中的用途 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2026147C (en) * | 1989-10-25 | 2006-02-07 | Ravi J. Chari | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US5208020A (en) * | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| UY24389A1 (es) * | 1995-12-06 | 2001-10-25 | Karlsruhe Forschzent | Composición farmacéutica para el tratamiento de carcinoma de epitelio plano |
| DE19648209A1 (de) * | 1996-11-21 | 1998-05-28 | Boehringer Ingelheim Int | Verfahren zur Tumorzelldepletion CD34-positiver Zellen |
| DE19708713C2 (de) * | 1997-03-04 | 2002-11-28 | Boehringer Ingelheim Int | Verwendung von anti-CD44 Antikörpern enthaltenden Präparationen zur Behandlung bestimmter Tumore und zur Unterdrückung von Immunreaktionen |
| EP1191944A2 (en) * | 1999-06-25 | 2002-04-03 | Genentech, Inc. | METHODS OF TREATMENT USING ANTI-ErbB ANTIBODY-MAYTANSINOID CONJUGATES |
| AU775373B2 (en) * | 1999-10-01 | 2004-07-29 | Immunogen, Inc. | Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents |
-
2001
- 2001-05-18 EP EP01112227A patent/EP1258255A1/en not_active Withdrawn
-
2002
- 2002-05-16 NZ NZ530167A patent/NZ530167A/en unknown
- 2002-05-16 MX MXPA03010432A patent/MXPA03010432A/es not_active Application Discontinuation
- 2002-05-16 WO PCT/EP2002/005413 patent/WO2002094325A2/en not_active Ceased
- 2002-05-16 HU HU0400046A patent/HUP0400046A3/hu unknown
- 2002-05-16 BR BR0209862-8A patent/BR0209862A/pt not_active IP Right Cessation
- 2002-05-16 PL PL02365480A patent/PL365480A1/xx not_active Application Discontinuation
- 2002-05-16 EP EP02753054A patent/EP1395290A2/en not_active Withdrawn
- 2002-05-16 JP JP2002591041A patent/JP2004529963A/ja active Pending
- 2002-05-16 SK SK1558-2003A patent/SK15582003A3/sk not_active Application Discontinuation
- 2002-05-16 YU YU91503A patent/YU91503A/sh unknown
- 2002-05-16 CN CNA028101634A patent/CN1509187A/zh active Pending
- 2002-05-16 EA EA200301159A patent/EA200301159A1/ru unknown
- 2002-05-16 EE EEP200300568A patent/EE200300568A/xx unknown
- 2002-05-16 HR HR20030932A patent/HRP20030932A2/xx not_active Application Discontinuation
- 2002-05-16 KR KR10-2003-7015037A patent/KR20030097883A/ko not_active Withdrawn
- 2002-05-16 IL IL15796502A patent/IL157965A0/xx unknown
- 2002-05-16 CA CA002443438A patent/CA2443438A1/en not_active Abandoned
- 2002-05-16 CZ CZ20033477A patent/CZ20033477A3/cs unknown
- 2002-05-17 AR ARP020101829A patent/AR035977A1/es not_active Application Discontinuation
- 2002-05-17 PE PE2002000420A patent/PE20021097A1/es not_active Application Discontinuation
-
2003
- 2003-09-22 ZA ZA200307364A patent/ZA200307364B/en unknown
- 2003-11-17 NO NO20035108A patent/NO20035108L/no not_active Application Discontinuation
- 2003-11-17 BG BG108366A patent/BG108366A/bg unknown
- 2003-11-18 CO CO03101695A patent/CO5550468A2/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CN1509187A (zh) | 2004-06-30 |
| EP1258255A1 (en) | 2002-11-20 |
| HUP0400046A3 (en) | 2006-02-28 |
| CA2443438A1 (en) | 2002-11-28 |
| MXPA03010432A (es) | 2004-04-02 |
| NZ530167A (en) | 2005-10-28 |
| SK15582003A3 (sk) | 2004-04-06 |
| YU91503A (sh) | 2006-05-25 |
| BG108366A (bg) | 2004-09-30 |
| WO2002094325A2 (en) | 2002-11-28 |
| CO5550468A2 (es) | 2005-08-31 |
| EE200300568A (et) | 2004-04-15 |
| JP2004529963A (ja) | 2004-09-30 |
| IL157965A0 (en) | 2004-03-28 |
| CZ20033477A3 (en) | 2004-05-12 |
| HUP0400046A2 (hu) | 2004-04-28 |
| NO20035108D0 (no) | 2003-11-17 |
| HRP20030932A2 (en) | 2004-04-30 |
| EP1395290A2 (en) | 2004-03-10 |
| NO20035108L (no) | 2003-11-17 |
| PL365480A1 (en) | 2005-01-10 |
| WO2002094325A3 (en) | 2003-04-17 |
| AR035977A1 (es) | 2004-07-28 |
| KR20030097883A (ko) | 2003-12-31 |
| PE20021097A1 (es) | 2003-02-13 |
| ZA200307364B (en) | 2004-04-20 |
| BR0209862A (pt) | 2004-06-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA200301159A1 (ru) | Цитотоксические иммуноконъюгаты антитела к cd44 | |
| WO2004018000A3 (en) | Compositions and methods for treating cancer using maytansinoid cd44 antibody immonoconjugates and chemotherapeutic agents | |
| DE60142342D1 (de) | Antikörper gegen doppelintegrinen, zusammensetzungen, verfahren und verwendungen | |
| ATE472338T1 (de) | Anti-cd70 antikörper-arzneimittelkonjugate und ihre verwendung zur behandlung von krebs | |
| CY1105349T1 (el) | Θειαζολυλ-αναστολεις τυροκινασεων της οικογενειας tec | |
| PL410219A1 (pl) | Kompozycja zawierająca koniugat leku obejmujący pochodne kalicheamycyny i przeciwciało, oraz kompozycja farmaceutyczna ją zawierająca | |
| BG66080B1 (bg) | Заместени тиоацетамиди | |
| EA200801509A1 (ru) | Человеческие моноклональные антитела к протеинтирозинкиназе 7 ( ptk7) и способы применения антител против ptk7 | |
| EE02962B1 (et) | Mometasoonfuroaadi monohüdraat, selle valmistamismeetod ja farmatseutilised kompositsioonid | |
| WO2002083171A3 (en) | Cancer treatment by using fap-alpha specific antibodies | |
| SE9802729D0 (sv) | Novel Compounds | |
| SE8605295L (sv) | Monoklonala antikroppar som er korsreaktiva och korsprotektiva mot p. aeruginosa-sero-typer | |
| ATE304866T1 (de) | Chelatorkonjugate mit verbesserten eigenschaften | |
| DE60033649D1 (de) | Verbindungen und therapeutische methoden | |
| IL176007A0 (en) | Antibodies specific to c35 and pharmaceutical compositions containing the same | |
| PL2161283T3 (pl) | Kompozycja zawierająca przeciwciała przeciwko CD79b skoniugowane ze środkiem hamującym wzrost lub środkiem cytotoksycznym i sposoby leczenia guzów o pochodzeniu hematopoetycznym | |
| IE870320L (en) | Cross-protective monoclonal antibodies. | |
| SE0003476D0 (sv) | Compounds | |
| ES2144054T3 (es) | Complejos de tri(platino). | |
| DE69921486D1 (de) | Dextran-leptin konjugate, pharmazeutische zusammentsetzungen und verbundene verfahren | |
| ID25478A (id) | Agonis 5-ht1f | |
| SE8702734D0 (sv) | Monoclonal antibodies to pseudomonas aeruginosa flagella | |
| EA200400670A1 (ru) | Фармацевтические композиции, содержащие 3,4-пропинопергидропурины, и их применение для блокирования нейронной передачи | |
| DE60006523D1 (de) | 3-(arylsulfonylamino)-tetrahydropyran-3-carbonsäure hydroxamide | |
| TR200103405T2 (tr) | İkiişlevli antikorlar ve bunların tümör-önleyici amilleri hedeflemede kullanımı. |